Key Takeaways
- Margin reset, not a demand crisis: EBITDA margin fell to ~19.5% from 27.1% YoY, driven by a one-time cost stack jump of ₹60-70 cr and a high base effect, while domestic formulations excluding anti-malarials still grew ~17%.
- Guidance cut across the board: Full-year sales growth guidance revised down to 9-10% and EBITDA margin to ~21%, as the company absorbs the impact of a UK distributor breakup, Losartan API disruption, and a fading COVID tailwind.
- The UK reset is a multi-quarter drag: Stopping dealings with a 25-year distributor over payment delays forces a transition to own distribution, with only 6 products launched so far and a recovery to 80-85% of prior business expected this year.
- Investment in the field force is front-loaded: ~800 of 1,200 planned new MRs have been hired, but each takes two years to break even, so selling costs will stay elevated while the revenue payoff is back-ended.
- What to watch next quarter: Whether the UK own-distribution ramp and cardiovascular restructuring deliver the promised Q2 improvement, and if raw material cost softening starts to flow through to margins.
Margin Walk: The Q1 Reset
- Cost stack jump: Q1 costs were elevated by ₹60-70 cr vs. the prior year, split across fuel (₹12 cr), freight (₹11 cr), field staff (₹14 cr), travel (₹6 cr), and sales promotion, with the field staff impact magnified because last year's base reflected only ~2 months of activity during the Delta wave.
- Material cost headwind: Material cost to total income rose ~1.33% YoY to 34.71% because higher-cost procurement inventory was consumed during the quarter, even though raw material and packing material prices have now started softening.
- Gross margin relief ahead: Management does not expect much further gross margin pressure, citing 20-25% cost reductions achieved on 3 major APIs and the internalization of 2 large intermediates previously imported from China, with benefits expected to start flowing in Q3/Q4.
- Tax rate adds to the bottom-line squeeze: The shift to a 25% tax regime (from 18% cash plus MAT credit) and disallowances on CSR and sales promotion items push the effective tax rate to ~27.5%, a structural headwind that management notes will hit the entire industry.
Jain: "So, EBIDTA from our last financial year, it's going down by almost around 2.25%. It's not 1%, 1% is from earlier guidelines."
UK Business: A Distributor Breakup and a Slow Rebuild
- The trigger: Ipca stopped dealing with a UK distributor of 25 years after payment delays stemming from the distributor's own financial deterioration tied to COVID, Brexit, and manufacturing troubles; management emphasized there were no disputes or litigation, only a payment-driven decision.
- The structural problem: All dossiers were registered in the distributor's name, so Ipca could not immediately switch to another partner or start its own distribution; the company is now building its own registration portfolio from scratch.
- The ramp so far: Six products have been launched under Ipca's own registration, with ~5-6 more approvals recently received and expected to launch in a few months; management expects ~8-10 more approvals during the year.
- Recovery timeline: The company expects to recover ~80-85% of the prior business (own plus residual distributor business) in the current year, with a small decline possibly remaining in FY23; from FY24 onwards, the business is expected to start doing well.
- Strategic lesson: Management stated the UK experience has changed its approach to distribution in Europe, with a shift away from single-distributor dependency.
Jain: "It was only because of payments not coming in time, we have said that we will not be able to do business and then, we will start our own distribution in the UK."
Domestic Formulations: Strong Underlying Growth, Masked by Base Effects
- The headline number: Overall domestic formulations growth guidance was revised down to ~12-13% for FY23, but this masks a sharp divergence: excluding anti-malarials, other therapies delivered ~17% growth in Q1, and the full-year ex-anti-malarial growth is expected at 17-20%.
- Anti-malarial collapse: The anti-malarial business declined ~68% YoY in Q1, from ₹39.5 cr to ~₹12.6 cr, and its share of domestic business fell from 6% to 2%; Q2 faces an even higher base from last year.
- Anti-bacterial normalization: Azithromycin revenue fell from ₹48 cr to ₹40 cr as the COVID-driven demand surge unwound, creating another base-effect drag on reported growth.
- Cardiovascular restructuring: Two new cardiac divisions were started to increase penetration in the chronic basket, but the move caused short-term disturbance in doctor-product relationships and coverage gaps, pulling Q1 cardiovascular growth down to ~5%; improvement is expected from Q2 onwards.
- Metro push working: Delhi, Calcutta, Mumbai, Hyderabad, Bangalore, and Chennai registered ~23% growth in Q1, driven by increased field force and focus on city-side coverage; India market share improved to ~1.85%.
- Pricing tailwind: WPI-based price increases for schedule formulations became effective from June/July after ~2 months of old inventory sell-through; non-schedule price increases are taken on a 12-month cycle, with the major rounds falling in Q2 and Q3.
Jain: "Our market shares are increasing, most therapies are doing well. So, it's the right time for us to increase our overall penetration in India and that's why this step is taken."
Field Force Investment: Paying Now, Earning Later
- The scale of the bet: Ipca plans to add ~1,200 medical representatives in FY23, with ~800 already recruited and the balance to be hired over the next two quarters; by year-end, the field force should reach almost 6,000.
- The cost today: Field staff costs were elevated by ₹14 cr in Q1, driven by the headcount increase and a 10-12% rise in daily allowances tied to higher fuel and food prices; the Q1 impact was magnified because last year's base reflected only ~2 months of field activity during the Delta wave.
- The payoff timeline: New MRs take approximately two years to recover their cost (salary, travel, supervision, promotion) and begin contributing to margin, so the full benefit of the current expansion will not materialize until FY25.
- Where they are going: Additions are focused on metro coverage and penetration in Rheumatoid Arthritis and Cardiovascular divisions, with two new cardiac divisions started and the Rheumatoid Arthritis division split to create one more.
Jain: "Normally, a rep takes two years' time to become productive. That's what our past experience is there. Productive means, I would say that he starts recovering his cost, his supervision costs all the promotional costs we incur on them, and then he starts contributing towards the margin."
API Business: Losartan Disruption and a Long-Term Bet
- The Q1 hit: API business declined ~10% YoY, mainly because of a sales return of Losartan tied to azido impurity concerns; the EU has since concluded there is no risk from impurity levels in earlier batches, and manufacturing processes have been improved to reduce impurity to drastically low levels.
- The competitive damage: Chinese suppliers entered the supply chain during the disruption; Ipca's initial process fix reduced impurities but drastically cut productivity and increased costs; a newer process is being registered to regain efficiencies, improve yields, and reduce costs. [23-24]
- Guidance reset: API growth guidance for FY23 was lowered to ~5%, with management acknowledging it will take time to aggressively compete and regain market share.
- The long-term aspiration: Management is targeting ~₹2,000 crores in API business over the next 3-4 years, supported by the new Dewas plant, a pipeline of newly commercialized products, and cost leadership on major products.
- Dewas timeline: The plant received its drug license ~10 days before the call and has started production of two intermediates; for the rest of FY23, it will only do establishment and validations of 5-6 APIs, with no turnover contribution this financial year and operating losses already factored into calculations.
Export Markets: Russia Recovers, Sri Lanka Slips, US Waits
- Russia: Q1 shipments were lost in April due to extreme Ruble volatility (120-125 to the dollar); billing was paused to avoid distributor reimbursement claims and resumed after the currency stabilized; the market is now doing well with inventory levels significantly down and business improving.
- Sri Lanka: Business lost ~₹5 cr in Q1 as demand was suppressed by affordability constraints, even though all payments were received on time via LCs; some reduction is expected vs. the prior year.
- US re-entry: No FDA inspections are scheduled yet, though plants are ready and inspections of Indian companies have resumed; management cautioned that after clearance, it will take time to win back customers (some tied up for 3-6 months) and that "nobody's waiting for me," requiring Ipca to disturb and recreate the market. [18-19]
- Branded formulation exports: Guided at 13-15% growth for FY23, with the Russia recovery and broader branded-market momentum offsetting the Sri Lanka drag; overall branded promotional markets are expected to deliver 10-15% growth.
Jain: "My disclaimer is that nobody's waiting for me. So, I had to go and disturb the market and create the market again."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Overall sales growth | 9-10% (revised down from 10-11%) | FY23 |
| Domestic formulations growth | ~12-13% (ex-anti-malarial: 17-20%) | FY23 |
| Export formulations growth | 13-15% | FY23 |
| Export generic growth | ~5% | FY23 |
| Institutional anti-malarial export | Decline ~8-10% | FY23 |
| API business growth | ~5% | FY23 |
| EBITDA margin | ~21% (revised down from ~22%) | FY23 |
| EBITDA margin recovery | ~23% "reasonably possible" | FY24 |
| UK business recovery | Recover ~80-85% of prior business | FY23 |
| Field force expansion | Add ~1,200 MRs (800 already recruited) | FY23 |
| New MR productivity | Breakeven and margin-contributing | Within ~2 years |
| API business aspiration | Reach ~₹2,000 crores | 3-4 years |
| Dewas plant commercial contribution | First business from India and data-submission markets | FY24 |
| Effective tax rate | ~27.5% to 28% | FY23 and future years |
Key Metrics
| Metric | Q1 FY23 |
|---|---|
| Revenue | ₹685 cr domestic formulations, +12% YoY from ₹613 cr |
| Domestic formulations growth ex-antimalarial | +17% YoY |
| Export formulations growth | +14% YoY |
| Export generics revenue | ₹213 cr, -2% YoY from ₹217 cr |
| Institutional anti-malarial export revenue | ₹97 cr, -17% YoY from ₹116 cr |
| API business growth | -10% YoY |
| EBITDA margin (standalone) | 19.5%, down from 27.1% in Q1 FY22 |
| EBITDA margin (adjusted for other income) | 17.9% (per an analyst's math) |
| Material cost to total income | 34.71%, up 1.33 ppt from 33.39% in Q1 FY22 |
| Deferred tax provision increase | ₹8.76 cr charged to P&L |
| Domestic market share | 1.85% |
| Field force size | ~6,000 sanctioned reps by year-end, ~800 of 1,200 planned additions already recruited |
| Metro cities growth (Delhi, Mumbai, etc.) | +23% YoY in Q1 |
| Pain management growth | +20% YoY in Q1 |
| FY23 EBITDA margin guidance | ~21%, revised from ~22% earlier and 23.25% in FY22 |
| FY23 overall sales growth guidance | 9–10%, revised from 10–11% |
| FY23 domestic formulations growth guidance | 12–13% |
| FY23 effective tax rate guidance | ~27.5% |